NewAmsterdam Pharma Company N.V. $NAMS Position Boosted by First Turn Management LLC

First Turn Management LLC lifted its stake in shares of NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) by 24.6% during the 4th quarter, HoldingsChannel.com reports. The firm owned 893,473 shares of the company’s stock after buying an additional 176,502 shares during the quarter. NewAmsterdam Pharma accounts for about 3.6% of First Turn Management LLC’s holdings, making the stock its 11th biggest holding. First Turn Management LLC’s holdings in NewAmsterdam Pharma were worth $31,343,000 as of its most recent SEC filing.

Several other large investors have also modified their holdings of NAMS. Farther Finance Advisors LLC lifted its position in shares of NewAmsterdam Pharma by 4,425.0% during the fourth quarter. Farther Finance Advisors LLC now owns 724 shares of the company’s stock worth $25,000 after purchasing an additional 708 shares during the last quarter. Wells Fargo & Company MN lifted its position in shares of NewAmsterdam Pharma by 50.0% during the fourth quarter. Wells Fargo & Company MN now owns 900 shares of the company’s stock worth $32,000 after purchasing an additional 300 shares during the last quarter. Navalign LLC bought a new position in shares of NewAmsterdam Pharma during the fourth quarter worth about $46,000. Empowered Funds LLC bought a new position in shares of NewAmsterdam Pharma during the fourth quarter worth about $85,000. Finally, NBC Securities Inc. bought a new position in shares of NewAmsterdam Pharma during the fourth quarter worth about $86,000. Institutional investors own 89.89% of the company’s stock.

Analyst Ratings Changes

Several equities analysts have recently commented on the stock. Truist Financial assumed coverage on shares of NewAmsterdam Pharma in a research report on Wednesday, March 18th. They set a “buy” rating and a $57.00 price target on the stock. Needham & Company LLC raised their target price on shares of NewAmsterdam Pharma from $46.00 to $48.00 and gave the stock a “buy” rating in a report on Wednesday, February 18th. Wall Street Zen raised shares of NewAmsterdam Pharma from a “sell” rating to a “hold” rating in a report on Saturday, May 9th. Guggenheim raised their target price on shares of NewAmsterdam Pharma from $41.00 to $45.00 and gave the stock a “buy” rating in a report on Thursday, February 19th. Finally, HC Wainwright raised shares of NewAmsterdam Pharma to a “strong-buy” rating in a report on Thursday, February 19th. One analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, NewAmsterdam Pharma has an average rating of “Moderate Buy” and a consensus price target of $48.60.

NewAmsterdam Pharma Stock Up 0.5%

Shares of NASDAQ NAMS opened at $30.40 on Friday. The firm’s 50-day moving average price is $33.44 and its two-hundred day moving average price is $33.69. NewAmsterdam Pharma Company N.V. has a 52-week low of $17.63 and a 52-week high of $42.21. The stock has a market capitalization of $3.55 billion, a P/E ratio of -16.98 and a beta of 0.07.

NewAmsterdam Pharma (NASDAQ:NAMS) last issued its earnings results on Tuesday, March 31st. The company reported ($0.40) earnings per share (EPS) for the quarter. NewAmsterdam Pharma had a negative return on equity of 26.49% and a negative net margin of 943.23%.The business had revenue of $3.04 million during the quarter. As a group, equities research analysts expect that NewAmsterdam Pharma Company N.V. will post -1.78 earnings per share for the current year.

Insider Buying and Selling at NewAmsterdam Pharma

In other news, CAO Louise Frederika Kooij sold 65,000 shares of NewAmsterdam Pharma stock in a transaction that occurred on Tuesday, May 26th. The stock was sold at an average price of $35.69, for a total transaction of $2,319,850.00. Following the sale, the chief accounting officer owned 24,353 shares of the company’s stock, valued at approximately $869,158.57. The trade was a 72.75% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Company insiders own 12.74% of the company’s stock.

About NewAmsterdam Pharma

NewAmsterdam Pharma, Inc is a clinical‐stage biopharmaceutical company focused on discovering and developing novel small‐molecule therapies for cardiometabolic diseases. The company’s research efforts are aimed at addressing key unmet needs in metabolic syndrome, obesity and type 2 diabetes by modulating pathways involved in glucose regulation, energy homeostasis and lipid metabolism.

The company’s development pipeline features multiple small‐molecule candidates at various stages of preclinical and clinical evaluation.